FLORHAM PARK, N.J., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Cellectar Biosciences, Inc. ( NASDAQ:CLRB ) , a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the U.S.

Cellectar生物科学

<p>新泽西州弗洛汉公园，2025 年 10 月 27 日（GLOBE NEWSWIRE）-- Cellectar 生物科学公司（NASDAQ:CLRB），一家专注于癌症治疗药物发现和开发的晚期临床生物制药公司，今天宣布了美国的消息</p>

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

Cellectar 生物科学的 Iopofosine I 131 用于复发或难治性儿科高级别胶质瘤，获得了美国食品药品监督管理局的罕见儿科疾病认定